good morning, it's 11:00 a.m. at pfizer headquarters in new york city. it's 11:00 a.m. on wall street and "squawk alley" is live

♪ good monday morning. i'm carl quintanilla with jon fortt. the dow puts together the first intraday high in nine months, processing the election, putting closure, perhaps, to that but obviously the big news of the day is out of pfizer and this potential covid-19 vaccine once again, we'll start the hour with meg >> hey, carl this news that pfizer and german partner biontech provided 90% efficacy in the phase three

trial providing hope this is the first vaccine we have seen results from the results are limited. they just -- the independent committee took a look at the trial. they found 94 confirmed cases of the covid-19 in the trial and they found a difference in the placebo group and the vaccine group. they also said they saw no serious safety concerns in the trial. they're going to he mass two months of safety followup which for half the people in the trial getting their second shot which will take them into the third week of november that is next week after which time they will file with the fachlt fda use authorization. a lot of question about the timing as pfizer had been talking about the end of october for knowing whether the vaccine worked and, of course, questions about tieing that announcement to the election we talked with the pfizer ceo about that timing this morning >> for us, the election was always a physical date we were not working with the

election as a time line. we were working to release a letter to our employees some time ago saying that the only pressure we feel it is the pressure of the billions of people that are hopping on our vaccine and we're going to follow the signs. so science spoke and i was predicting that this will happen at the end of october. it happened a week later i think the most important thing we have now for everyone is to feel the joy it happened and happened so well >> the trump administration's effort to bring a vaccine to the american people, here are the investments that operation warp speed is making since february you can see all of the funding the research and development into the vaccines. these are the later awards they made pfizer, they made an award on july 22nd for $2 billion

that was exclusively a supply deal and pfizer would only get paid by biontech and only get paid if the vaccine succeeded and given fda cleernz. we're going to wait for the process but only then would they get the $2 billion it's the different from the rest of operation warp speed. manufacture the companies were funded along the way by the development process. guys, the next question is supply there is not going to be enough of this drug -- this vaccine they say 50 million doses by the end of 2020. $1.3 billion doses in 20 1.3 billion doses by 2021. we asked about that situation. here's what he told us >> given how effective this vaccine is and we are aware about the demand will be much higher than anything we can produce. we are also looking right now to

see if there are other ways thinking out of the box to increase even further the manufacturing capacity now so there's no time to relax here. >> so they're not the only companies in this race here's what they said in terms of the production goals. moderna aiming to have 20 million by 2021. this is a two dose vaccine they should have data any week now. they said november and that works in the same way as pfizer's vaccine works. so we'll see fit works as well now as as stothers expected to data by the end of the year. all hands on deck to get vaccine out to everybody in the world that wants to get vaccinated to get immunity and finally stop this pandemic. >> meg, it's great news, of course, but we're in these unchartered territories where i

wonder what happens to these other potential vaccines is it possible that we end up with a case where there are multiple vaccines with varying efficacy and, you know, some are two doses. there are different numbers of doses. and it just depends what can you get and when >> yeah. it could be very complicated, john we see how the vaccines work in trials it's also possible that the vaccines might work better for some populations than others for older people, for example, people with underlying conditions and so people are very curious to see how that worked out in the pfizer-biontech data so as these start to get rolled out, they get the clearance from the fda, they get recommended by a cdc group, the advisory committee on immunization practices will say which groups should get which vaccines. that is how this the start to

look throughout next year. and think about the flu shot now. there are actually multiple different flu shots on the market right now there are ones that protect against three strains. there are some that protect against four there is a nasal spray there is one that doesn't use eggs we don't realize that unless you have an allergy or you want the nasal spray or over 65 and you want the high dose we're not asking what the flu shot is. there is so much attention being paid to this and we know the companies involved and seeing the data rollout real time it might be that you say oh, the pfizer looks 90% i want to see if they got it this is tightly controlled at the beginning. there will be certain groups for whom they're indicated but it's going to be very interesting market that perhaps might resemble the flu shot market way down the line we're going to have to see how it goes. >> right when you think about mass immunizations next year, do you see it more as a hospital, doctor office, you know, urban clinic kind of delivery system

or do you see long lines in the military being involved? in terms of retail participation? >> the military is going to be involved in the distribution, that's for sure. but in terms of the retail participation, you know, we started hearing about pharmacies, the trump administration struck a deal with pharmacies to get people in nursing homes vaccinated it is surprising if it was the military in the front thaend consumers are interacting with but they'll be extremely involved in the logistics of making all of this happen. >> right we're about to learn a lot more about pharmaceutical logistics storage and distribution over the next couple months meg, thank you once again, thank you. joining us to talk about the market impact, of course, david katz over at matrix asset advisors and tony roth good monday morning, guys. good to see you. >> nice to see you

>> thanks for having us. >> david, let's talk about where risk is at the moment. we got this blockbuster news we don't know what the president's intentions are on transition senate control is not for sure we still got to get through the fall >> we have a lot more clarity than we did a week ago the presidential election is decided by president lekt bid-en is the president that's .1. we hope the the first point. this is the hunl first step. it takes a lot of risk off the table in terms of the economy, we're in a recovery mode on the economy front and we think that continues into 2021. so these are all great for humanity and also very good for our financial markets.

>> tony, i still see notes today that say the market may still have good licks in it before year end you think that's true? >> yeah. i mean, i think we start with what david said. i agree with david 100%. a large amount of the large systemic medium to long term risk is taken out of the picture. having said that, there are definitely some shorter term risks that create volatility a lot of them are on the political side of the equation and i'll start with the new administration and with the makeup of the senate so coming into the morning this morning, let's remember that futures were down. that's been lost in the noise of the vaccine. the reason they were down is because i think the market was reckonning with the fact that there was a not a material chance that the democrats might actually get the senate. now it's a fighting chance it's not a great chance. but the chance does exist. with the two seats in georgia. we need to see what cabinet president biden puts together

and how progressive he's going to be in his approach, even apart from legislation j ust jif just in terms of running the major departments. there is also risk around the virus and the increase in cases and whether we overwhelm our hospital system. how people respond to that and lockdowns. then, of course, risk around the possibility of more fiscal stimulus and, frankly, the vaccine increases that risk. in the shorm tet term, there ar risks. we're on a much better path. >> david, it seems, following up on that, like first of all we're probably a year out from mass numbers of people being vaccinated based on what wear heerg at th we're hearing at this point. and the democrats taking the senate and the markets were supposedly booming on the possibilities of a blue wave and more stimulus?

>> well, last week you had a very significant rally like 6% or 7% on the expectation of a biden win and a split government if the democrats were to take the senate, there is more uncertainty about the economy in terms of the bank group and regulation and taxes net-net, we looked at 1946 to 2019 and overall the market actually does a little bit better under democrats if the democrats control everything, it's good. if the democrats can control the presidency and the prrepublican control the senate and house that, is the economic scenario for the stock market regardless of biden victory and a sweep, it's good for the stock market overall and the conomy. and if there is a split, it is a little better for the stock market and the economy we would not be changing the asset allocation based on the biden victory. >> tony, what are the main most important risks at this point mean, we know that covid-19 is

still a factor in the near term. a little bit more confidence longer term perhaps. but is the attention now to policy we expect the republicans in the senate to get serious about the budget again >> well, i think the biggest risk really is ironically when we're saying divided government is risk, there is risk around inaction so there is a lot of risk that this administration is locked up with the divide between very, very difficult senate led by mcconnell with a government that really wants to get some legislation accomplished so they're going to need to come together they need to really use the legacy that they have between biden and mcconnell to get things done in order to move the economy forward in different ways and pursue some agenda that is bipartisan as opposed to not accomplishing anything at all. but i do think that from the public health care standpoint, we're rounding the corner of

getting out of the woods here in term of the longer term tra jekt ric trajectory and it's very exciting >> i saw one reference to reagan-o'neal as trying to make an an log between bid biden-mcconnell. >> that's right. >> have a great day. >> while pfizer and biontech on to dates, cnbc treatment index is in negative territory as other players in the space fall behind you're deeg big declines in names like biogen, lots of them. we'll keep an eye on those "squawk alley" continues on the other sidef isre oth bak (upbeat music)

- we did it! (crowd cheering) - [narrator] wherever you start, snhu is where you can finish. (crowd clapping) (crowd cheering) - here we go. - [narrator] and it's it. - [group] yay! - [narrator] you did it, high five! - southern new hampshire university. - [man] that gets a hug. (laughing) - look at that! master's degree, i did it! - i did this for my children. i am very proud of myself. - [narrator] finish your degree at snhu.edu.

let's turn back to the morning's big news out of pfizer cnbc contributor walter isaacson joins us now he was a part of the trial as well as dr. peric from nyu's infectious disease unit. welcome to both of you walter, quite a moment here. i take it you still don't know, of course, whether you have the placebo or the actual vaccine. but tell us what's exciting about this type of vaccine and where you think things head from here >> when i was first reading

about this vaccine, i've been writing a book about the use of rna in order to edit genes i really lot of notion of what rna can do and this vaccine is an rna vaccine. it takes a rna and goes into the cell and tells the cells protein making section to start making this protein and that's what happens here this mrna in the pfizer-biontech vaccine and also in the moderna vaccine which will be come ago long soon is instructed to make this protein of the coronavirus. so i live in new orleans i just went down to oxnard hospital in new orleans. louisiana, there is a lot of trials going on. and i volunteered for the trial and as they said, they put a big needle in my arm the doctor said, look me in the eyes he was standing on the other side to make sure i didn't even see the needle, didn't see the

vaccine. i said would i be able to tell the placebo from the real thing? he said, you probably couldn't but we don't take any chances. >> right doctor, i don't know that we have seen anything like this where there's a vaccine that the people who want vaccines are certainly going to want this one or one of the competitors on the market what's your sense of the best possibilities organizationally for getting this out to people at the rate necessary? and making sure that people get the right follow up doses to make sure it completes >> right you know, the logistics are going to be very important because pfizer as well as moderna and some of the others may have two doses which are about four weeks apart. so we have to make sure people get both doses also pfizer has to be stored at a very, very cold temperature. so that is even colder than the on average freezer. not every doctor's office or

facility is equipped for that yet. we need to make sure all of that in place before we have a wide scale rollout so there's no slowdown or bottle necking >> walter, what would you say right now about overall vaccine acceptance in this country if it's not good enough, do you think it improves by the time this is readily available. >> i think people are so eager to get back out there and get back doing things that people will want this vaccine they may not do it in the first few weeks. but they'll be -- these two and within the next six months probably be four, five other vaccines i think once people taking them, they'll be safe. when i went through this clinical trial, i had zero worry that it would be unsafe. nobody sticking some live coronavirus into your veins. so it wasn't clear whether it would be effective we know the things are sachfe

it didn't even hurt. i just tell everybody, make sure you get the vaccine. it's not -- you know, i didn't -- i was wondering would i grow an extra finger or something? no no i think people are start accepting. this man, we can't continue to accept what we have now which is not being able to go out, not being able to hug your kids. >> doctor, two concerns i have i wonder if you could address. one is the one that you just brought up about what it's going to take to store this vaccine effectively. how big a logistical challenge is that? and then second, something i've seen around testing is that companies often have the resources to make sure their employees get tested more often, depending on, you know, the resources of the company what are the mechanisms in place to make sure it's the most vulnerable populations that get this vaccine first not just those with resources >> so already we've put out the

indication and so has the fda that as soon as it's approved, the high risk groups will have first priority so that includes health care workers, elderly, those with diabetes, heart disease, obesity and in those high risk health disparity groups now the logistical problems are definitely going to be a challenge. the first time in history for a long time where everybody's clambering for the same vaccine. and the storage of it is crucial. if we don't have enough places that have these subzero freezers, it may be very difficult to store vaccine and deploy the vaccine in a timely manner so luckily there is multiple vaccine candidates and not all of them have to be at the subzero temperatures so we'll have options. >> all right well, i hope there is plenty of transparency around this doctor and walter, i appreciate it, thank you.

>> thanks. nice being with you, carl. >> and walter, thanks for taking part on behalf of all of us. by the way, keep an eye on the retailers today. we're seeing a lot of underperformance in the names that have done well and benefited through this initial wave of coronavirus. take a look at walmart, costco, kroger home improvement names selling off. home depot for a while there the lone dow kpoen necomponent n negative territory stay with us (♪ ) keeping your oysters growing while keeping your business growing has you swamped. (♪ ) you need to hire i need indeed indeed you do. the moment you sponsor a job on indeed you get a shortlist of quality candidates from a resume data base so you can start hiring right away.

claim your seventy-five-dollar credit when you post your first job at indeed.com/promo

vaccine news is affecting just about every asset class today. take a look at the ten year. yield hit a high today of 97 1/2 basis points that's the highest level since march 20 we have come down a touch from that we approach 1% back in main

get real-time insights in your customized view of the market. it's smarter trading technology for smarter trading decisions. fidelity. do you have a life insurance policy you no longer need? now you can sell your policy, even a term policy, for an immediate cash payment. we thought we had planned carefully for our retirement. but we quickly realized that we needed a way to supplement our income. if you have one hundred thousand dollars or more of life insurance you may qualify to sell your policy. don't cancel or let your policy lapse without finding out what it's worth. visit conventrydirect.com to find out if you policy qualifies. or call the number on your screen. coventry direct, redefining insurance.

welcome back, everybody. i'm sue herrera. in new jersey, governor phil murphy will reportedly ban indoor service at bars and restaurants from 10:00 p.m. until 5:00 a.m it is one of a number of new

pandemic restrictions set to be announced to day as new cases there have risen >> the associated press is reporting the trump campaign's election fraud claims and lawsuits are more about keeping the trump base loyal than changing the outcome of the election that report is based on discussions with ten senior trump officials. the kremlin says russian president putin will not congratulate president-elect joe biden until legal challenges to the election results are resolved and the result is official and in georgia, senate candidate john ossoff challenged david purdue to three debates. purdue refused to participate in the last debate scheduled ahead of election day. you're up to date. carl, back to you. >> okay. sue, thank you very much we'll talk to you in a bit turn back to the markets once again. global market strategist over at jp morgan asset management joins us and head of u.s. equity and

derivative strategy. quite a morning, guys. thanks for joining us. >> thank you >> of course, thanks for having me >> david, you got the whole financial sector up seven. you have the whole energy sector up 12. is this an overreaction or a legitimate response to news that we've literally waited most of the year for >> i think it's a pretty legitimate response. you know, we spend a lot of time over the past eight months talking about how the trade worked going into and coming out of covid-19 has been fairly one sided and primarily focused on growth and mega cap tech will all of these other names were just left in the rubble but we have the view that eventually either the outperformers that we're going to need to catch down or they're going to need to catch up. with respect to the financial story, i think a lot of it is about rates, obviously, ten year pretty significantly higher on the day. the energy story i think is just more of a data trade the more less bad news, more clarity about the direction of travel lift being the cyclical parts of the market that are so beaten up over the course of the

year thus far. >> greg, how you would separate what is tactical for the most part and what is sustainable if you're going to buy today and hold for the medium term here? >> well, i think the idea of a rotation into value is a sustainable theme. we can see it play out in 2021 it may take a more different shape to the knee jerk reaction than we've seen this morning i think be the financial sectors, surprising given the yield curve move this morning. there is this knee jerk positive reaction a question mark whether that can be sustained in an environment where we do see yields as very much capped by the fed we think the other parts of the cyclical world such as the industrials and cyclical plays can fair better in the medium term. >> this is kind of rational. but onest things i don't get, look at peloton. it's down 14.5% right now. i mean, what, people think everybody's going back to the gym because, david, the -- this

vaccine news is out today. i don't see how that necessarily makes sense unless there's a belief that peloton was just trading on sentiment >> no, i think it's a fair point. you know, markets tend to overreact to things like this. we have been waiting for vacancy seen for a very long time. a lot of the stuff had simply been left by the way side. i wouldn't make too much out of that move in particular. i would say first off, there is a lot we don't know about the vaccine. it's very difficult to transport multiple doses are required. so now getting into the logistics. we have bird in hand, figuring out how to deliver it is a different story. i would go a step further and say consumer preferences haven't done a 180 but consumer preferences changed and we got better at working from home, working remotely, not necessarily going to the gym if we want to get exercise. i wouldn't put a whole lot of credence into that move today. i think that there are broader

structural forces at play which will continue to support the tech oriented and consumer oriented names going forward there is opportunity there from where we sit this is a little bit of a pause. >> what's a trader to do then? i imagine you think the swings are going too far on either side so do you take advantage of that to some extent now and if you're not a trader, if you're an investor zshgs th investor, does that mean you sit on your hands? >> you can't necessarily sit on your hands outlook is one where we still have incredibly low rates environment. but the spreads are really tight. there are places to count returns other than the equity market there is clearly massive swings and lornarge rotation. you have to worry about getting caught up in these things. there are tactical opportunities to trade the rotation. i think what we focus on is 2021, where do we see the sustainable winners?

so i think looking for value stocks that are less likely to be value traps so we will focus on the value oriented tech, for example so maybe tech hardware, semis, cyclical parts of tech where the valuations aren't necessarily as stretched as some of the growth names. industrial cyclicals, infrastructure plays, those are names we do think could benefit from a sustained cyclical pickup, a suppression in equity volatility and we think there is a good story there for 2021. >> how patient the will market be if they hear we have enough gas in the tank without stimulus to get to next year? and more importantly if, it starts to see poll numbers in the georgia runoffs that they don't like >> i think you latched on to two of the big risks the one, first is going to be ensuring that there is adequate policy support you see lockdowns put into place

in europe. you talk about what is happening in new jersey. policy is still very much the bridge that needs to get to the other side of this pandemic. the reality is we make it through the end of the sphere and that is more significant stimulus tend of 2021. what i would say about the georgia senate race is that's the wild card. that's the black swan. both of those seats go to the democrats and wend up with that very unlikely blue wave scenario at this point. i think you'll see some of the wind come out of the sails of the equity market. >> right that's a long time to wait for answers. the markets had to do that all year long, guys. appreciate it. great to see you both. thank you. >> today's vaccine news having a big positive impact on travel names including airlines phil lebeau has more >> they're all up anywhere between 12% and 14%. one exception being hawaiian up more than 30%. we all know what's been going on as far as quarantines and how

that's hurt travel to hawaii so as you take a look at the airline stocks, keep a couple things in mind yes, this was expected that you'd see a pop and there was kind of positive news when it comes to a vaccine the airlines are in a very deep hole in terms of a, travel coming back, how quickly it comes back, and they've got massive debt out there how much has travel congress about a? take a look at the passenger levels we're going to be showing this all the way back to when the pandemic began and you see that it has recovered a little bit but still down 59% yesterday it's nowhere close to getting where it was in february and early march. you take a look at the large airlines, we're talking about american, delta, and united. it's no the just these guys. it's really all airlines but these guys in particular, they're debt, no the just these guys, but the airline industry overall, it barrowed more than $42 billion this year and that is going to be weighing on these

stocks over the next year, two years, three years take a look at shares of southwest. we're showing you southwest. while it has done a much better job than the competitors in terms of not having to borrow as much, it is in the midst of negotiations with its pilots union about pay cuts they realize it's going to be a while until we truly see people coming back and flying again in large numbers. jon? >> all right thank you, phil. >> and we mentioned peloton. some more of the year's high flying stay at home stocks plunging today zoom video, chegg, docusign are down 10% holding on to big gains for 2020 but they're off 20% from the recent highs don't go anywhere. ua aaeacinwosqwklg bk t

hey! yeah!? i switched to geico and got more! more savings on car insurance!? they helped with homeowners, too! ok! plus motorcycle, boat and rv insurance!

geico's got you covered! like a blanket! houston? you seeing this? geico. expect great savings and a whole lot more. what does today's pfizer news mean for the cruise lines we break down the time line. >> the biggest winners on the is s&p 500 right now, jon, royal caribbean ceo said a vaccine is the ultimate weapon in this covid-19 fight booking holdings in past interviews on "squawk alley" said a vaccine is the new passport to travel so this news today is certainly encouraging to say the least what it really does from a wall street perspective is it potentially speeds up the time line on when travel demand can return to precovid-19 levels:that will be in focus when norwegian cruise lines reports earnings they still have a number of hurdles before they can get the all clear to go back to sea.

they're using this month, november, to conduct the simulated voyages with volunteers to test their covid-19 protocols with hopes to start sailing january 1st. now in terms of stock performance today, worth noting carnival the largest cruise line. it is up 30% on the day. that is now on pace for the best day ever since the ipo in july of 1987. carl, you look at royal caribbean up 23% also on track for the best day since march of 2020. so certainly some big moves here >> all right thank you very much. we'll take a break here. one of the members of the president-elect biden's coronavirus task force will join us with the dow up still more than 1,000 points. don't go anywhere. change is all around us.

shaped by technology and human ingenuity, we can make it work for you and your business. ♪ (har(betsy) twelquarter mile of tinsel. lights. (harold) and real snow all the way from switzerland. (betsy) hmmhm... gonna be tough to top. ♪ (betsy) well played. (vo) add some thrill to your wish list. at the season of audi sales event. get exceptional offers now.

the pfizer vaccine news brought about a bunch of reversals. we're watching some of them. >> big reversals needs a lot more to change the big secular type themes. let's start with one of the big themes developing with regard to how we consume entertainment we saw many theater operators and live entertainment venues take massive hits. amc entertainment up 66% as the prospects for theaters reopening with normalcy with the covid-19 vaccine playing out. netflix, meanwhile, has been a huge outperformer is down 5%

just how big a difference has it been well, take a look at this chart year to date between netflix and amc. the theater operator look at this amc is down 43% so far this year netflix is up 51%. so reversal there. just to put context longer term between some of the terms kind of rebalancing and removing around let's take a look at another one. this is the workout effect peloton versus some of the app in person type gyms. pl planet fitness up 16%. pel sewn is down 15% to 16%. over the course of the last year to date period planet fitness and peloton peloton is up 270% year to date versus just 4% for planet fitness. again, a bit of a reversal here taking place on right side of your screen. to cap things off, because we love threes, check out this move in retail. brick & mortar traditional retail versus online retailers

macy's up 14% today. yes, it's been a hugely hit stock in this pandemic wayfair, online retail, down 17%. moving lower after a big gain. check out the year to date performance though macy's versus wayfair. you don't need more than one guess here wayfair is a huge outperformer macy's is down 55% a lot of key reversals happening now. again, it's going to take a jon fortt, a lot more than today's moves to change some of the themes i'm going to look out of the corner of my eye i can kind see you out here much that's a big move for sure >> yeah, you're here seven, eight paces >> far enough away >> joe biden announced the members of his coronavirus advisory board we're now joined by one of those members dr. michael ostroholm from the university of

minnesota. welcome and good morning >> thank you >> thank you >> you have been talking about how to fight pandemics for a long time. your book "deadliest enemy: our war against killer germs," first tell me about this pfizer news that we had this morning to what extent if at all does that affect the work of a task force or advisory group like the one that you're joining? >> well, i can't comment on the task force yet that work yet still to be done i'm excited that it's happening. and very supportive of the efforts. on the vaccine itself, i think there are a lot of conclusions drawn this morning that are premature. while the vaccine reported out 90% effectiveness for efficacy that, is a great, great finding. but what we don't know is 90% protecting against fever, cough and chills or 90% of protecting against serious illness and

death? until we have those pieces of information, we can't really know how much of a game changer this really is so we have to be very careful in interpreting this 90% number >> it sounds like that has big impact potentially on the economy, what people can and can't do tell me the rates that you see of hospitalizations and how those are trending during this period when we got better at treating covid-19 and the rate of deaths. how much does that factor into the types of recommendations that make sense based on trying to, of course, take care of public health but also keep the economy moving >> yeah. first of all, it's a false notion to keep the economy going versus covid-19. when covid-19 is running out of control, the economy is going to be suffering mightily. so the thing swrez s we have too get covid-19 under control will effect the economy in a positive way. look no further than asia. asia has done a remarkable job

of krig tbringing the cases undr control and look at they're economy. let's talk about the issue you raised about the number of deaths what america has to understand is we're about to enter covid-19 hell it is happening. you know, ten weeks ago, i mean, the prediction that after labor day to describe you're out in the front line battlefield you'll see what's happening. the quality of care is going to drop precipitously when we don't have all the intensive care doctors and nurses and teams

that's what's brought us the much, much lower iffatality rats you're going to see those increase substantially the next three to four months are going to be, by far, the darkest of the pandemic. >> we're seeing some stories even today about capacity in el paso at the same time, though, we got a new mask mandate out of utah and some dining restrictions out of new jersey today. are public officials at the state level reacting in time to make that dark picture a little less dark? >> first of all, all the cases we're going to add in the next three weeks are basically in the pipeline we had a miraculous change in behavior, we saw people not going into large crowds be not dining and eating out, not

congregating in places like gyms and so forth, we will still have a major challenge on our hand. what we're concerned about particularly as we're going into the holiday season where we're going to see lots of travel and transmission in our homes today is a very major source of transmission when you bring people in from the outside i don't think america gets this yet. this is going to get much worse. this is not to scare people out of their wits, it's to scare people into their wits it's still in our control. if not, everything i just laid out, the case numbers, we're going to look back one day and say oh my god, 100,000 cases a day, i wish we were back at that point. that's the challenge is helping people see the future and knowing they can do a tremendous amount about controlling that.

>> the president-elect tweets he spent the mork with his co-chairs of the covid-19 council talking about the pandemic and how we move forward. i don't want to pin you down unfairly or try to scare people. it was newsworthy -- forgive me, let's listen to the president-elect. >> i said on saturday i'm humbled by the confidence that the american people have put on me and vice president-elect harris today that work begins and that's to do everything possible to get covid-19 under control so we can reopen our businesses safely, sustainably, resume our

lives and put this pandemic behind us. we just received positive news in this fight with the announcement that there's been progress made toward a successful vaccine soon the expectation is the fda will run the process of rigorous reviews and approval the process must also be grounded in sign and fully transparent so the american people can have every confidence that any approved vaccine is safe and effective at the same time, it's clear that this vaccine, even if approved, will not be widely available in the months to come. the problem is still immense and growing. although we are not in office yet, we are laying out what woo can expect to do

so the purpose is to let you know what we're going to do. there are now nearly 10 million cases in the united states last week we topped 120,000 new cases on multiple successive days infection rates are going up, hospitalizations are going up, deaths are going up. this crisis claimed nearly a thousand american lives a day, nearly 240,000 deaths so far the projections still indicate we could lose 200,000 more lives in the coming months before a vehicl vaccine can be made widely available. we can't forget the work that needs to be done now and then to get the country through the worst wave that's why today i named a covid-19 transition advisory board comprised of distinguished public health experts who help

our transition team translate the biden covid-19 program into action we will seek to add other members to this board, that will bring additional important perspectives on public expertis transition they will provide detailed plans built on a bedrock in science, making rapid testing much more widely available and building a core of contact tracers who will track and curb this disease. developing clear and detailed guidance, providing the necessary resources for small businesses, schools, child care centers to reopen and operate

safely and effectively during the pandemic, protecting both workers and the public scaling up productive life saving treatments and therapeutics and when it's ready, making sure an approved vaccine is distributed equitably and efficiently and free for r american cases rising once more, it's imperative we ramp up our production of personal protective equipment to make sure our brave health care workers have what they need to do battle safely against this virus. we're going to get states, cities and tribes the tests and supplies they need we're going to protect vulnerable populations most at risk from this virus, older americans and those with preexisting conditions and we're going to address the health and economic disparities that means this virus is hitting the black, latino,

native-americ native-americans more than other communities. the bottom line, i will spare no effort to turn this pandemic around once we're sworn in on january 20th, to get our kids back to school safely, our businesses growing and our economy running at full speed again and to get an approved vaccine manufactured and distributed as quickly as possible to as many americans as possible free of charge. we'll follow the science we'll follow the science let me say that again. i will adjust the new data when it comes in and we'll listen and work in cooperation with governors and local leaders of both parties who are fighting this virus in their communities this very day. there is so much good work happening at state and local levels across the country, governors and mayors they're stepping you

advisory boards will listen and learn lessons from their experience my advisory council also includes experts on global health security so that we can restore the u.s. global leadership to fight this pandemic this is a crisis that affects everyone as i've said throughout this campaign, i will be a president for every american this election is over. it's time to put aside the partisanship and the rhetoric that is designed to demonize one another and time to end the politicization of mask wearing and social distancing. we have to come together to heal the soul of this country so we can effectively address this crisis as one company where hard-working americans have each other's back and we're united in our sthahared goal, defeating ts virus. as you work toward a safe and

effective vaccine, we know the single most effective thing we can do to stop the spread of covid, wear a mask the head of the cdc warned this fall, for the foreseeable future, a mask remains the most potent weapon against the virus. today's news does not change that urgent reality. i won't be president until january 20th but my message today is to everyone is this, it doesn't matter who you voted for or where you stood governor election day it doesn't matter your party, your point of view, we can save tens of thousands of lives if everyone would just wear a mask to are the next few months, not democrat or republican lives, american lives maybe we'll save the life of a person who stocks the shelves